S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Investing

SciClone Cancels Development of New Drug (SCLN)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Specialty drug maker SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) announced this morning that the company will “discontinue development” of its SCV-07 oral mucositis drug because the drug failed to “meet the pre-specified efficacy endpoints” of the phase 2b trials.

From the company’s announcement:

SciClone is notifying the FDA and study investigators of the trial’s discontinuation. No additional patients will be enrolled in the trial. Dosing of subjects currently enrolled in the trial will be discontinued, but subjects will be followed per protocol for a full year.

The company noted that there were no safety issues with SCV-07. The drug simply did not do what it was intended to do.

SciClone’s shares closed at $4.52 yesterday, in a 52-week range of $3.30-$6.88.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble
Chris Lange |

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble

Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely…
Celgene Faces Multiple Clinical Holds From FDA
Chris Lange |

Celgene Faces Multiple Clinical Holds From FDA

Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove…
5 FDA COVID-19 Decisions in July Could Make or Break Stocks
Chris Lange |

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July…
Chris Lange |

4 New Big FDA Decisions Expected in September

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and…
Massive Biopharma Movers of the Past Week
Chris Lange |

Massive Biopharma Movers of the Past Week

A few biopharma stocks made massive runs over the course of this past week, some losing more than half their…
Key FDA Decisions and Trial Results Coming in the Next 2 Months
Chris Lange |

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…
Can Epizyme Survive This FDA Hold?
Chris Lange |

Can Epizyme Survive This FDA Hold?

Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the…
AstraZeneca Cuts Almost All Ties to Inovio Pharma
Chris Lange |

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.
Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results
Chris Lange |

Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results

Corbus Pharmaceuticals shares skyrocketed on Monday morning after the company announced positive results from its mid-stage clinical trial in systemic…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618